From Sea Sponge to Clinical Trials: Starting the Journey of the Novel Compound PM742.

Mar Drugs

Research and Development, PharmaMar S.A., Pol. Ind. La Mina Norte, Avda. de los Reyes 1, 28770 Colmenar Viejo, Spain.

Published: July 2024

PM742 (), a new chemical entity, has been isolated from the sponge collected in the Pacific Ocean. This compound showed strong in vitro cytotoxicity against several human tumor cell lines as well as a tubulin depolymerization mechanism of action, which led us to conduct an extensive Structure-Activity-Relationship study through the synthesis of different analogs. As a result, a derivatively named PM534 () is currently in its first human Phase I clinical trial. Herein, we present a comprehensive review of the isolation, structural elucidation, and antitumor activities of the parent compound PM742.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11355788PMC
http://dx.doi.org/10.3390/md22080339DOI Listing

Publication Analysis

Top Keywords

compound pm742
8
sea sponge
4
sponge clinical
4
clinical trials
4
trials starting
4
starting journey
4
journey novel
4
novel compound
4
pm742 pm742
4
pm742 chemical
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!